About codexis inc - CDXS
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
CDXS At a Glance
Codexis, Inc.
200 Penobscot Drive
Redwood City, California 94063-4718
| Phone | 1-650-421-8100 | Revenue | 59.35M | |
| Industry | Chemicals: Specialty | Net Income | -65,276,000.00 | |
| Sector | Process Industries | Employees | 188 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CDXS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.90 |
| Price to Book Ratio | 5.834 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.692 |
| Enterprise Value to Sales | 5.663 |
| Total Debt to Enterprise Value | 0.178 |
CDXS Efficiency
| Revenue/Employee | 315,664.894 |
| Income Per Employee | -347,212.766 |
| Receivables Turnover | 3.143 |
| Total Asset Turnover | 0.416 |
CDXS Liquidity
| Current Ratio | 4.177 |
| Quick Ratio | 4.101 |
| Cash Ratio | 3.128 |
CDXS Profitability
| Gross Margin | 64.39 |
| Operating Margin | -98.33 |
| Pretax Margin | -109.937 |
| Net Margin | -109.994 |
| Return on Assets | -45.716 |
| Return on Equity | -85.027 |
| Return on Total Capital | -51.471 |
| Return on Invested Capital | -58.582 |
CDXS Capital Structure
| Total Debt to Total Equity | 89.493 |
| Total Debt to Total Capital | 47.228 |
| Total Debt to Total Assets | 40.195 |
| Long-Term Debt to Equity | 85.269 |
| Long-Term Debt to Total Capital | 44.999 |